Generally, loss of HER2, ER, and PR expression refers to as triple-negative breast cancer cells (e.g., MDA-MB-231), while ER and PR positive cells were less malignant as luminal A breast cancer cells (e.g., MCF-7). This evidence concerns the gene ESR1 and triple-negative breast carcinoma.